In Britain, the life-time risk of lung cancer in men who smoke 20 or more cigarettes per day is about 15%. That most smokers never develop lung cancer has promoted interest in the role of host factors. While chance, other environmental factors and the competing effect of other diseases, some of which are also smoking related, are all likely to affect individual lung cancer risk, genetic factors may also be important. This review examines the evidence for genetic predisposition to smoking related lung cancer.
In Britain, the life-time risk of lung cancer in men who smoke 20 or more cigarettes per day is about 15%. That most smokers never develop lung cancer has promoted interest in the role of host factors. While chance, other environmental factors and the competing effect of other diseases, some of which are also smoking related, are all likely to affect individual lung cancer risk, genetic factors may also be important. This review examines the evidence for genetic predisposition to smoking related lung cancer.
The review concentrates on the numerous metabolic studies that have sought differences between individuals in the genetic control of biochemical pathways that could be involved in the metabolism of carcinogens in tobacco smoke. Insights gained are likely to have wider implications for other environmental carcinogens. Other studies that have sought simple evidence, such as familial clustering or associations of lung cancer with blood group, HLA and other naturally occurring antigens, are also examined. The field of chromosomal abnormalities in lung cancer and the difficulties in interpreting them is reviewed only briefly, since this area may not directly relate to tobacco smoking and has been reviewed elsewhere (Birrer & Minna, 1988) . Various sources of bias important in the interpretation of the metabolic studies in particular are outlined. Future research is likely to be dominated by the recent advances in molecular genetics that offer the possibility of circumventing bias by the direct identification of genes, but at present this is possible only to a limited extent.
Familial clustering of lung cancer cases
Familial clustering of a cancer (or indeed of any disease) is an insensitive indicator of genetic predisposition. Peto (1980) and Bodmer (1986) have pointed out that a cancer can have a major genetic component yet show no detectable familial clustering. The ratio of the incidence of the cancer in relatives of known cases to that in age-matched controls is the only measure of familial clustering (in the absence of a marker). This ratio will be much smaller than the ratio of the incidence in genetically susceptible to non-susceptible individuals, which is the direct measure of the magnitude of the genetic effect. It is a question of dilution -not all patients with cancer will be genetically susceptible individuals, fewer of their relatives will be, and tne general population contains susceptibles as well as non-susceptibles. The effect of such dilution is greater than may intuitively be assumed. Using the model of a single autosomal gene that affects cancer risk, and assigning various values for gene frequency and the increased risk of cancer in genetically susceptible individuals, Peto (1980) showed that even with a very large cancer risk in susceptibles, the incidence of cancer in relatives will generally be increased by no more than 1.5-3-fold. It is difficult in a family study to show that such a modest increase could not be due to chance, shared exposure or other bias.
Five studies have examined lung cancer incidence in relatives of cases, but three (Tokuhata & Lilienfeld, 1963b;  Lynch et al., 1982 Lynch et al., , 1986 did not take into account the fact that relatives of lung cancer patients are themselves more likely than average to be smokers (Tokuhata & Lilienfeld, 1963a) and so have increased lung cancer risk. Tokuhata and Lilienfeld (1963a) and Ooi et al. (1986) separately compared smoking and non-smoking relatives and their results are summarised in Table I . Both studies found about a 3-fold increased lung cancer incidence in both smoking and nonsmoking relatives of lung cancer patients. This could correspond to a much larger genetic effect if it were real, but a relative risk of three could readily be produced by bias. Possible sources of bias in these studies include familial sharing of the same environment (e.g. asbestos exposure), family history recall bias among lung cancer patients compared to controls (independent confirmation of causes of death in relatives was often incomplete), and the possibility that relatives of cancer patients may on average be heavier smokers than control relatives and also may be more likely to claim falsely to be non-smokers (smokers who deny the habit may constitute a small minority of all 'non-smokers' but will contribute substantially to their lung cancer incidence). Consistent with the latter possibility is the observation of higher mortality from non-malignant respiratory diseases among both 'smoking' and 'non-smoking' relatives of cases (Tokuhata & Lilienfeld, 1963a ). The increased lung cancer incidence in relatives of cases is therefore consistent with any interpretation, from a large genetic effect to bias with no genetic effect at all. To demonstrate genetic predisposition to lung cancer a marker associated with the predisposition must be identified.
Reports of clustering of cancer in individual families are generally of limited value, but the report of Paul et al. (1987) of alveolar cell carcinoma (which is not smoking related) developing in three brothers suggests genetic predisposition because of the extreme rarity of this cancer. While such familial clustering need not be genetic (it might be a viral infection), the three brothers shared HLA-A28 (population frequency 5%) while a fourth unaffected sibling lacked HLA-A28. Studies in mice suggest autosomal dominant inheritance of alveolar cell carcinoma (Paul et al., 1987) . Joishy (1977) reported simultaneous onset of alveolar cell carcinoma in identical twins.
NaturaUy occurring antigens and chromosomal abnormalities as genetic markers of lung cancer risk
The distribution of ABO and Rh blood groups in lung cancer cases was compared to the general population in eight studies (Aird et al., 1954; McConnell et al., 1955; Parker & Walsh, 1958; Rennie & Haber, 1961; Jakoubkova & Majsky, 1965; Ashley, 1969; Roberts et al., 1988; Roots et al., 1988) . A deficit of group 0 in lung cancer observed in the last study was not supported by the other seven, and various associations of blood groups with certain histological types and with proximal tumours reported by Ashley (1969) were again not present in the other studies. Beckman et al. (1986) reported the distribution of haptoglobin groups in lung cancer patients and controls and reviewed three similar studies -an association in their own study was not present in the others. Of five studies that have sought associations between HLA antigens Bodmer (1986) has shown that such associations of two unrelated genes on the same chromosome could have persisted (in the absence of natural selection) only with extremely close linkage, with recombination fraction approaching 0.1%.
Various chromosomal abnormalities (deletions and rearrangements) have been observed in lung cancer, small cell in particular, notably the deletion of chromosome 3p. Birrer and Minna (1988) have reviewed these and other aspects of molecular genetics in lung cancer. There is a general difficulty in determining whether chromosomal abnormalities preceded the cancer or were produced by the genetic instability resulting from malignant transformation. The latter appears less likely in the study of Yokota et al. (1987) , testing both cancerous and normal lung tissue from 47 patients against markers for 24 restriction fragment length polymorphisms. A high incidence of allelic deletions was found in small cell lung cancer at three chromosomal loci (3p, 13q and 17p). The putative retinoblastoma (Rb) gene is located on 13q, and this gene is associated with small cell lung cancer by the finding of abnormalities of its structure and expression (Harbour et al., 1988) and by a case report (Leonard et al., 1988) .
Metabolism offoreign chemicals (including potential carcinogens)
It is usually metabolites of environmental carcinogens, rather than the parent compounds, that initiate a cancer (Miller, 1978; Farber, 1981) , and many studies have sought genetically determined differences between individuals in the extent to which metabolities are generated. The metabolism to water soluble products is common to many chemicals foreign to the body and exists to facilitate excretion, since the parent compounds, being highly fat soluble but hydrophobic, may be very slowly excreted. There are two phases to the metabolism (Nebert, 1981) , summarised in Figure 1 . In phase I a 'handle' is attached to the molecule, commonly by insertion of an oxygen atom, to form a reactive intermediate substance, which in phase II is conjugated though the 'handle' with an endogenous compound to become water-soluble and readily excreted.
Phase I mono-oxygenation Phase I mono-oxygenation is performed by the cytochrome P-450 microsomal enzyme system, present in many tissues including lung (Gonzalez et al., 1986) . (The colour in the cell that the name implies is imparted by haeme, a pigment (P) with peak optical absorption wavelength of 450 nm.) Among the many structurally diverse substrates of the P-450 enzymes are various combustion products in tobacco smoke including polycyclic aromatic hydrocarbons and nitrosamines. The system is probably coded for by at least 50 genes (Wolf, 1986) . It is classified (arbitrarily by structural similarity between P-450 proteins) into families and sub-families of P-450 enzymes, but their substrate specificities overlap and different systems of nomenclature exist (Wolf, 1986; . Some sub-families exhibit detectable activity only after 'induction' (a period of exposure to certain foreign compounds that induce the production of a large number of copies of the enzyme); preferential induction of specific isoenzymes active against the inducing agent itself is common. (The greater tolerance to alcohol of regular drinkers than occasional drinkers is an example.) Other P-450 sub-families are constitutively expressed, exhibiting activity without induction.
Phase II conjugation
After phase I mono-oxygenation, foreign compounds are sometimes sufficiently water soluble to be excreted, but more commonly they are first made more water soluble by conjugation with endogenous compounds. Examples are the conjugation of benzo[a]pyrene with glucuronic acid, sulphate and glutathione (Figure 1) , and the acetylation of the drug isoniazid (discussed below).
Production of carcinogen-DNA adducts Oxygenated phase I intermediate substances on occasion do not proceed to conjugation but bind covalently and nonenzymatically with centres on nucleic acids and proteins, and such a combination with DNA may initiate carcinogenesis (Miller, 1978; Farber, 1981; Miller & Miller, 1983; Pelkonen & Nebert, 1982) . The generation of such carcinogen-DNA adducts might be increased, with resultant predisposition to lung cancer, either by genetically determined increased monooxygenating activity or by genetically determined reduced conjugating (phase II) activity (Figure 1 ). Figure 1 ) with over 40 metabolites in all (Gelboin, 1980) . Epoxides (three-membered cyclic ethers formed by one oxygen and two carbon atoms) or, more specifically, arene oxides are reactive intermediate metabolites of PAHs that have been shown experimentally to bind to DNA causing mutation and malignant transformation of cells (Gelboin, 1980; Conney, 1982; Pelkonen & Nebert, 1982) . Cultured human bronchus can produce carcinogen-DNA adducts (Harris et al., 1980 other PAHs. AHH activity is highly inducible, but non-induced activity is low, and the term 'inducibility' (or 'fold induction') refers to the ratio of the two. Induced and non-induced activity represent different cytochrome P-450 sub-families (Meehan et al., 1988b; Arnott et al., 1979) . Which, if any, of these measures of AHH activity is most relevant to the in vivo situation is uncertain, as is the relationship of the maximally induced AHH activity which is measured to 'usual' AHH activity in smokers. Some studies report induced AHH activity, others report inducibility. Jett et al. (1978) Assay limitations Reproducibility of the fluorometric assay in particular is limited, and influenced by many extraneous factors including length of incubation, starting cell density, duration of storage, season and geographical latitude Korsgaard & Trell, 1978; Cantrell et al., 1973; Arnott et al., 1979) . There are further problems in lymphocyte AHH assays. To provide detectable amounts of enzyme, proliferation of lymphocytes must first be stimulated by mitogens: the extent of proliferation varies between individuals, declines with age, may be influenced by cancer and depends on additional technical factors such as lot of fetal calf serum and nature of mitogen. The proportions of the different types of mononuclear cells vary.
Genetic control of AHH activity Mice The earlier work of Nebert et al. (1972) identified some inbred strains of mice where AHH activity was inducible in all individuals, some strains where it was never inducible and other strains that included inducers and noninducers. Breeding experiments between the strains showed that induction was determined by a single genetic locus, termed the Ah locus (for aryl hydrocarbon). The observation that in wild mice (and humans) induction is continuously distributed and not 'all or nothing' suggested that other genes were also important but did not differ between the inbred mice strains studied.
More recent work has shown that the Ah locus is a regulatory one that determines the induction of many structural loci controlling enzymes responsible for foreign compound metabolism (Gonalez et al., 1986) . The Ah locus has been assigned to chromosome 12 in the mouse (Cobb et al., 1987) . Its major product is a cytosolic receptor that binds inducing compounds, then migrates to the nucleus (Okey et al., 1980) . Increased cytochrome P,-450 mRNA synthesis follows (Israel & Whitlock, 1984) . The conjugating enzymes glutathione transferase and UDP glucuronyl transferase (Figure 1) are also likely to be induced (Lang & Nebert, 1981) . Only one structural locus, mapped by Hildebrand et al. (1985) to chromosome 9, appears to influence cytochrome P1-450 activity in mice (Hankinson et al., 1985) . Other cytochrome P-450 sub-families also contribute to induced AHH activity as stated above. Constitutive (non-induced) AHH activity in mice (much lower than induced activity) has been mapped to a different P-450 structural locus, on chromosome 19 (Meehan et al., 1988b) .
Human studies Cell culture experiments in humans have identified the regulatory Ah locus and assigned it to chromosome 2 (Wiebel et al., 1981; Ocraft et al., 1985) . Amsbaugh et al. (1986) have isolated the human PI-450 structural locus. As in mice, other cytochrome P-450 subfamilies also contribute to AHH activity, notably P-450-2C (Shimada et al., 1986) , with structural locus on chromosome 10 (Meehan et al., 1988a of AHH activity, in keeping with polygenic control. In three twin studies (Atlas et al., 1976; Okuda et al., 1977; Paigen et al., 1978) , intra-pair differences in AHH induction for monozygous twins were similar to that of the same individual measured twice, but for dizygous twins were small for most pairs but larger for a few, suggesting that the number of genes influencing induced AHH activity is fairly small but exceeds one. Emery et al. (1978) stated that their unpublished family study favoured polygenic inheritance.
All studies concur that there is large variation (which could be genetically determined) only in induced AHH activity. Non-induced activity shows little variation, and as mentioned above is likely to represent a different cytochrome P-450 family.
Environmental determinants of AHH activity Many environmental factors influence in vivo AHH activity, and several may bias case-control studies in lung cancer. Cigarette smoking increases AHH activity in the lung and in tissues distant from the lung -both baseline and induced levels are higher in smokers than non-smokers (Conney, 1982; Cantrell et al., 1973) . Other factors associated with cancer that may influence AHH activity include serum cholesterol (Korsgaard & Trell, 1978) and asbestos exposure (Snodgrass et al., 1981) , while several dietary factors (which may change with hospital admission) also affect AHH activity (Conney, 1982 (Oesch et al., 1980; Karki et al., 1987) ; the reason is uncertain.
The studies of human lung tissue are essentially negative. Table II summarises four case-control comparisons of AHH activity in lung tissue. One (Oesch et al., 1980) found higher activity in cases (statistically significant for non-smokers but not smokers) but the difference was only about 2-fold and might readily have been produced by bias. The three other controlled studies were negative. Also, McLemore et al. (1978b) reported no difference between lung cancer cases and controls in AHH activity in pulmonary alveolar macrophages obtained by lavage. In three uncontrolled studies (Harris et al., 1976; Cohen et al., 1979; Sabadie et al., 1981) , AHH activity in cultured bronchus or peripheral lung tissue of patients with lung cancer showed, like the controlled studies, wide unimodal distribution (20-, 44-and Karki et al., 1987) .
The results of the case-control comparisons of lymphocyte AHH activity in lung cancer conflict. They are summarised in Table III . The first such study (Kellermann et al., 1973a, b) , widely cited, reported that high and intermediate AHH inducers, 9% and 46% of the population, had 37 and 16 times respectively the lung cancer risk of low inducers (45% of the population). Subsequent studies did not reproduce these results, but some later studies have also reported higher AHH inducibility in lung cancer cases than controls, and of all the studies (Table III) (Jett et al., 1979) and there was no significant difference in the other (Rudiger et al., 1980 Kalamegham et al. (1979) in biopsied liver (r = -0.52) and by Atlas et al. (1976) and Boobis et al. (1981) measuring AHH inducibility in cultured lymphocytes (r= -0.55 and r = -0.84). With hindsight AP was not an appropriate choice as a potential marker drug. The above correlations were modest because AP has three major metabolites generated by different metabolic pathways which are likely to be controlled by different cytochrome P-450 sub-families (Danhof & Breimer, 1979; Boobis et al., 1981) , whose relative contribution to AP half-life varies between individuals. AP Genetic control of AP metabolism In keeping with the observation that three different metabolic pathways contribute variably to AP half-life, two twin studies (Atlas et al., 1976; Vesell et al., 1971) have shown intra-pair correlation coefficients for AP half-life to be high (>0.9) for nine monozygous twin pairs but almost zero for nine dizygous twin pairs, and Blain et al. (1982) found that correlation of AP half-life between first degree relatives was about as high as between spouses. Distribution of AP halflife is wide and unimodal (Atlas et al., 1976; Kellermann et al., 1980) . All the evidence indicates that AP metabolism is regulated by many genes.
Environmental determinants of AP metabolism Many environmental factors influence AP metabolism. Indeed the main relevance of the antipyrine studies is perhaps to illustrate how metabolic studies may be biased by factors associated with cancer and illness, including weight loss and changes in diet, alcohol intake and smoking. Thus AP elimination is accelerated by smoking (Kellermann et al., 1980; Hart et al., 1976) , alcohol and caffeine (Vestal et al., 1975) , and prolonged by liver disease (Branch et al., 1973) , hypoxia (Cumming, 1976) and bed-rest (Vesell, 1979) . Many drugs and dietary factors also influence its clearance (Vesell, 1979) . Elimination is slower in older than younger subjects (Vestal et al., 1975; O'Malley et al., 1971) and in men than women (Cumming, 1976) . AP half-life is shorter in subjects with lower body weight (Ayesh & Idle, 1985) .
Evidence for an association between AP metabolism and lung cancer Five studies that have compared AP clearance from saliva or plasma in lung cases and controls are summarised in Table  IV . Ambre et al. (1977) found significantly higher clearance in cases as did Kellermann et al. (1980) if the non-smoking controls, rather than the smoking controls, are considered appropriate (most cases had stopped smoking for three months or so). Three other studies found no difference, including Danhof (1980) , who measured not only overall clearance but also 48 h urinary excretion of four separate AP metabolites. The two positive results could readily have been produced by case-control differences in one or more of the environmental factors discussed above.
Debrisoquine as a drug marker of phase I mono-oxygenation Rationale The anti-hypertensive drug debrisoquine is a more appropriate drug marker for phase I mono-oxygenation. It has only one important metabolite, 4-hydroxydebrisoquine (Idle et al., 1979 ). The drug is partly excreted unchanged and the extent of 4-hydroxylation before excretion, reflecting the activity of the 4-hydroxylation pathway, varies widely between individuals (Idle et al., 1979; Sloan et al., 1983) , the variation being substantially genetically determined as discussed below. Individual metabolism of over 20 drugs and other chemicals correlates with that of debrisoquine (Eichelbaum, 1984 (Steiner et al., 1985) . The gene has been assigned by genetic linkage to chromosome 22 (Eichelbaum et al., 1987) , and complementary DNA has been cloned . (Steiner et al., 1985) . The distribution of metabolic ratio among extensive metabolisers is skewed to the right by certain drugs (Law et al., 1989) (Kato et al., 1968; Rosso et al., 1971) , (n = 9) (n = 9) matched for medication Danhof (1980) 1 h-3.1 (0.6) 2.9 (1.0) Also, no difference in 48 h (n = 10) (n = 9) excretion of 4 metabolites Ayesh & Idle (1985) ml min-' kg-' such a bias again operating against an association of extensive hydroxylation with lung cancer.
Evidence for an association between debrisoquine hydroxylation and lung cancer (Caporaso et al., 1989) . (Cartwright et al., 1982) . Acetylation is not associated with lung cancer risk (Philip et al., 1988; Roots et al., 1988) , but conjugating enzymes involved in PAH metabolism (Figure 1) (Seidegard & Pero, 1985) A more limited application could lie in the selection of low-risk workers for occupations involving risk of lung cancer (Caporaso et al., 1989) 
Conclusions
Genetic factors must contribute to lung cancer risk, since it is the metabolites of environmental carcinogens that usually initiate a cancer, and the metabolic pathways are genetically controlled. The studies reviewed have examined the question of whether significant genetically determined variation in risk exists between individuals, and some of the evidence suggests that it does.
The studies of familial clustering are too insensitive to be useful, and are consistent with any interpretation from a substantial genetic effect to no genetic effect at all; a marker is needed to demonstrate genetic predisposition. Associations of lung cancer with two naturally occurring antigens, the a4 Aa-ras allele and the HLA-B12 allele, may be important but they require confirmation. The evidence linking small cell lung cancer with the retinoblastoma (Rb) gene and with 3p chromosomal deletions is suggestive, and there is good evidence for genetic predisposition in at least some cases of the rare alveolar cell carcinoma, which is not smokingrelated.
The numerous studies of PAH metabolism in smokingrelated lung cancer cannot collectively constitute convincing evidence for genetic predisposition to lung cancer. Ah dominant mice showed predisposition to PAH-induced lung cancer, but this experimental model need not be relevant to tobacco smoking in humans. The control of AHH activity in humans is polygenic. The case-control studies measuring AHH activity directly in lung tissue, one lymphocyte study in which the cancer in cases had been resected (reducing possible bias from biological effects of cancer), and the two lymphocyte studies that measured DNA binding were all negative (Tables II and III) . One study has shown higher induced AHH activity in lung cancer, but non-carcinogenic metabolites were measured remote from the lung, and some sources of bias could not be excluded. The one positive study cannot outweigh the negative evidence. The association of low conjugating enzyme activity with lung cancer in one study is interesting, but the result may have been produced by differences in smoking habit or other bias and requires confirmation.
Antipyrine is not a suitable drug to investigate the genetic determinants of lung cancer. Debrisoquine is, since 4-hydroxylation is its only major metabolic pathway and is dominated by a single gene. The greater risk of lung cancer in extensive compared to poor metabolisers of debrisoquine, confirmed in four studies, is compelling evidence for genetic predisposition. No known environmental factor could plausibly account for this difference, and it is in any case uncommon for environmental factors to have so powerful an effect on mono-oxidation as to reproduce the 10-200-fold genetically determined difference in mean metabolic ratio between poor and extensive debrisoquine metabolisers. Debrisoquine 4-hydroxylation is not associated with the monooxygenation of either PAHs or nitosamines, but there could be a shared metabolic pathway with another carcinogenic tobacco smoke constituent. Alternatively, however, the association with lung cancer might be explained by linkage disequilibrium, the gene regulating debrisoquine hydroxylation being chromosomally linked to another gene that directly affects lung cancer risk. There is thus no definite evidence for a metabolic mechanism in genetic predisposition to lung cancer. An ongogene for example might account for the associations of lung cancer with both debrisoquine metabolism and the retinoblastoma gene.
The size of the genetically determined variation between individuals in lung cancer risk is unresolved. To propose a genetic basis for the observation that only about 15% of smokers develop lung cancer implies that a minority of the population is at high risk, but there is little evidence for this. The debrisoquine studies identify homozygous recessives, 10% of the population, at about a 4-fold reduced risk; homozygous dominants are likely to be at higher risk than heterozygous dominants, if the two could be reliably distinguished, but the difference in risk would not be large. The studies of naturally occurring antigens suggest that about 15-25% of the population have about a 2-fold increased risk (though an incomplete association with the antigen that serves as a marker could dilute the real risk), and the unconfirmed conjugating enzyme study suggests a 2.5-3-fold increased risk in about half the population. In summary, there is some variation between individuals in genetically determined lung cancer risk, but as yet no evidence for substantially increased risk in a minority of the population.
The main interest of this work is the understanding of the biology of cancer, not public health. To screen smokers for genetically determined lung cancer risk is impractical because so many other diseases are also caused by smoking. An occupational application might be feasible but this is unlikely and certainly not imminent. Any future metabolic studies should avoid the various biases (mostly consequent on the illness of the cases) that have affected the existing studies. This could be done in a longitudinal study, metabolic activity being measured (or blood or urine stored) in healthy smokers and a comparison made between those who subsequently developed lung cancer and matched controls who did not. Trell et al. (1985) have commenced such a study measuring AHH activity. Many subjects and long follow-up would be necessary. Alternatively, the bias inherent in previous case-control studies might be minimised by studying only long-term (say 5-year) survivors of resection for lung cancer. Bias associated with drugs, hospital stay and illness would be eliminated, and bias from a metabolic effect of cancer substantially avoided. This type of study could be performed quickly and economically. However, developments in molecular genetics promise attractive studies that would circumvent all bias. This approach is likely to dominate future research.
